Review article: explaining risks of inflammatory bowel disease therapy to patients

被引:90
作者
Siegel, C. A. [1 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Ctr Inflammatory Bowel Dis, Sect Gastroenterol & Hepatol, Lebanon, NH 03756 USA
关键词
CROHNS-DISEASE; CORTICOSTEROID-THERAPY; RHEUMATOID-ARTHRITIS; DECISION-MAKING; METHOTREXATE; INFLIXIMAB; BENEFITS; COMMUNICATION; AZATHIOPRINE; LYMPHOMA;
D O I
10.1111/j.1365-2036.2010.04489.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P>Background Medical treatment for inflammatory bowel disease (IBD) has advanced significantly over the past decade, but it is important to communicate effectively the balance of benefits and risks of therapy to patients to facilitate informed medical decisions. Aim To review the available data describing the risk of side effects of IBD medications and to describe effective methods for communicating risk. Methods To identify relevant articles for this review, a PubMed search was conducted using relevant key words and phrases. In addition, reference lists from identified manuscripts were searched and recent abstracts from National meetings were reviewed. Results The steroid-sparing medications used for the treatment of IBD all carry risks of both common and rare adverse events. Trade-offs need to be made between the risks of these medications vs. the risks of poorly treated disease and corticosteroids. There has been significant research on how best to present risk data to patients, which is summarized in this review. Conclusions To ensure that our patients understand their choices and feel comfortable with their treatment, we need to communicate risk data to patients clearly. Patients comprehend absolute numbers better than relative risk, and when available, pictorial representations of data are preferred over solely presenting numerical outcomes.
引用
收藏
页码:23 / 32
页数:10
相关论文
共 51 条
  • [1] Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis - A multicenter, case-control study
    Alarcon, GS
    Kremer, JM
    Macaluso, M
    Weinblatt, ME
    Cannon, GW
    Palmer, WR
    StClair, EW
    Sundy, JS
    Alexander, RW
    Smith, GJW
    Axiotis, CA
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 127 (05) : 356 - +
  • [2] Patients' Preferences regarding Shared Decision-Making in the Treatment of Inflammatory Bowel Disease: Results from a Patient-Empowerment Study
    Baars, Judith E.
    Markus, Tineke
    Kuipers, Ernst J.
    van der Woude, C. Janneke
    [J]. DIGESTION, 2010, 81 (02) : 113 - 119
  • [3] Patient's Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease
    Baars, Judith E.
    Siegel, Corey A.
    Kuipers, Ernst J.
    van der Woude, C. Janneke
    [J]. DIGESTION, 2009, 79 (01) : 30 - 35
  • [4] Rheumatoid arthritis and malignant lymphomas
    Baecklund, E
    Askling, J
    Rosenquist, R
    Ekbom, A
    Klareskog, L
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (03) : 254 - 261
  • [5] Predictors of Crohn's disease
    Beaugerie, L
    Seksik, P
    Nion-Larmurier, I
    Gendre, JP
    Cosnes, J
    [J]. GASTROENTEROLOGY, 2006, 130 (03) : 650 - 656
  • [6] Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
    Beaugerie, Laurent
    Brousse, Nicole
    Bouvier, Anne Marie
    Colombel, Jean Frederic
    Lemann, Marc
    Cosnes, Jacques
    Hebuterne, Xavier
    Cortot, Antoine
    Bouhnik, Yoram
    Gendre, Jean Pierre
    Simon, Tabassome
    Maynadie, Marc
    Hermine, Olivier
    Faivre, Jean
    Carrat, Fabrice
    [J]. LANCET, 2009, 374 (9701) : 1617 - 1625
  • [7] Bernstein KI, 2010, INFLAMM BOWEL DIS
  • [8] Patients' understanding of risk associated with medication use - Impact of European Commission guidelines and other risk scales
    Berry, DC
    Raynor, DK
    Knapp, P
    Bersellini, E
    [J]. DRUG SAFETY, 2003, 26 (01) : 1 - 11
  • [9] BOHON P, 1993, ACTA GASTRO-ENT BELG, V56, P352
  • [10] *CENT INC, 2010, DAT FIL